Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
m Tag: visualeditor |
m Tag: visualeditor |
||
| Line 1: | Line 1: | ||
| − | == | + | {| class="wikitable" style="text-align:center; width:100%;" |
| + | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' | ||
| + | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editor''' | ||
| + | |- | ||
| + | | style="background-color:#F0F0F0; width:15%" |[[File:Amit_Kulkarni.jpg|frameless|upright=0.3|center|link=https://hemonc.org/wiki/File:Amit_Kulkarni.jpg]] | ||
| + | | style="width:35%" |<big>[[User:Akulkarni|Amit Kulkarni, MBBS]]</big><big>University of Minnesota</big><big>Minneapolis, MN</big>[[File:Social-twitter-icon.png|frameless|upright=0.1|link=https://hemonc.org/wiki/File:Social-twitter-icon.png]][https://twitter.com/AmitKulkarniMD AmitKulkarniMD] | ||
| + | | style="background-color:#F0F0F0" |[[File:TravisOsterman.jpg|frameless|upright=0.3|center|link=https://hemonc.org/wiki/File:TravisOsterman.jpg]] | ||
| + | |<big>[[User:Travisosterman|Travis Osterman, DO, MS]]</big><big>Vanderbilt University</big><big>Nashville, TN</big>[[File:Social-twitter-icon.png|frameless|upright=0.1|link=https://hemonc.org/wiki/File:Social-twitter-icon.png]][https://twitter.com/TravisOsterman TravisOsterman][https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn] | ||
| + | |} | ||
| + | Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens. | ||
| + | == Metastatic disease == | ||
| + | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| + | |- | ||
| + | |<div align="right" style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>1 [[Tutorial#Regimens|regimens]] on this page</b></font></div><div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
| + | |} | ||
===Selpercatinib monotherpay=== | ===Selpercatinib monotherpay=== | ||
'''Regimen''' | '''Regimen''' | ||
Revision as of 03:34, 14 July 2020
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBSUniversity of MinnesotaMinneapolis, MN AmitKulkarniMD
|
 |
Travis Osterman, DO, MSVanderbilt UniversityNashville, TNTravisOstermanLinkedIn
|
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
Metastatic disease
1 regimens on this page 7 variants on this page
|
Selpercatinib monotherpay
Regimen
| FDA-recommended dose |
|---|
| Study | Years of enrollment | Evidence |
|---|---|---|
| Drilon et al. 2019
LIBRETTO-001 |
Phase I/II |
Biomarker eligibility criteria
- Biomarker: RET fusion positive
Chemotherapy
- Selpercatinib 120 mg (<50 kg) and 160 mg (>50 kg) orally twice daily with or without food
Continued indefinitely
References
- Abstract. Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. link to abstract.